Patrick G Wisniewski, RN, BSN 604 Apple Road Newark DE 19711-5122 (302) 737-6440

Dockets Management Branch (HFA-305) Docket No. 98N-1265 Food and Drug Administration 5600 Fishers Lane Rockville, MD 02857 1493 '99 MAR 24 AIO :35

To Whom It May Concern,

March 19, 1999

I am a health professional and a lifelong celiac. Celiac Disease, as you may know, is a particularly troubling autoimmune disorder. A person with Celiac Disease (celiac) may be mis-diagnosed for many years, as the disease presents in such a variable manner. Once diagnosed, complete avoidance of certain prolamins, found in glutens, must be strictly adhered to in a celiac's diet.

The problem of ferreting out hidden glutens is a daily, full-time task for a celiac. One area of concern, among many, is the question of gluten-free medications. Many celiacs have relied upon Formulating Pharmacies for the safe preparation of many of their medication needs. The proposal to limit the interstate transfer of formulated medications would put celiacs at risk. Often there are no safe alternatives to be found in mainstream pharmaceutical offerings. In addition, many manufacturers use a variety of ingredients, based upon economic decisions and availability of raw materials. Thus a medication that is safe may in the next manufacturing lot be altered, rendering it unusable by a celiac.

There is evidence that ingestion of hidden glutens increases a celiacs likelihood of contracting lymphomas and intestinal cancers at a rate that far exceeds the non-celiac population.

Please consider this information as you weigh the merits and risks of implementing the proposed legislation.

Respectfully,

Patrick G Wisniewski, RN, BSN

984-1265

CH48



PO Box 1668 Wilmington, Delaware 19899-1668





Dockets Management Branch (HFA-305) Docket No. 98N-1265 Food and Drug Administration 5600 Fishers Lane Rockville, MD 02857

Intellement of the state of the